RU2017115191A - Производные бороновой кислоты - Google Patents
Производные бороновой кислоты Download PDFInfo
- Publication number
- RU2017115191A RU2017115191A RU2017115191A RU2017115191A RU2017115191A RU 2017115191 A RU2017115191 A RU 2017115191A RU 2017115191 A RU2017115191 A RU 2017115191A RU 2017115191 A RU2017115191 A RU 2017115191A RU 2017115191 A RU2017115191 A RU 2017115191A
- Authority
- RU
- Russia
- Prior art keywords
- ethyl
- amino
- boronic acid
- phenyl
- och
- Prior art date
Links
- 150000001642 boronic acid derivatives Chemical class 0.000 title 1
- -1 C3-C6 cycloalkyl radical Chemical class 0.000 claims 123
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 229940002612 prodrug Drugs 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 8
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 5
- DECHLHGALUDGHL-ZDUSSCGKSA-N [(1r)-2-(1-benzofuran-3-yl)-1-[[2-[methyl(methylsulfonyl)amino]acetyl]amino]ethyl]boronic acid Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN(C)S(C)(=O)=O)B(O)O)=COC2=C1 DECHLHGALUDGHL-ZDUSSCGKSA-N 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 235000015067 sauces Nutrition 0.000 claims 5
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 3
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 3
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 3
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 3
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 3
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 3
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims 2
- 125000005916 2-methylpentyl group Chemical group 0.000 claims 2
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 claims 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- 125000005917 3-methylpentyl group Chemical group 0.000 claims 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000004799 bromophenyl group Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000007365 immunoregulation Effects 0.000 claims 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000003944 tolyl group Chemical group 0.000 claims 2
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- OECQEAJHEXSOTF-SFHVURJKSA-N C(C)(=O)N(C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O Chemical compound C(C)(=O)N(C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O OECQEAJHEXSOTF-SFHVURJKSA-N 0.000 claims 1
- XVUNRNPJPCAKMF-HNNXBMFYSA-N C(C)(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)S(=O)(=O)C Chemical compound C(C)(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)S(=O)(=O)C XVUNRNPJPCAKMF-HNNXBMFYSA-N 0.000 claims 1
- WQNPKUHJTLWJTP-HNNXBMFYSA-N C(C)C=1C=C(C=CC=1)C[C@H](NC(CCCCS(=O)(=O)C)=O)B(O)O Chemical compound C(C)C=1C=C(C=CC=1)C[C@H](NC(CCCCS(=O)(=O)C)=O)B(O)O WQNPKUHJTLWJTP-HNNXBMFYSA-N 0.000 claims 1
- AIQWWVDEOPVPNJ-AWEZNQCLSA-N C(C)C=1C=C(C=CC=1)C[C@H](NC(CCCS(=O)(=O)C)=O)B(O)O Chemical compound C(C)C=1C=C(C=CC=1)C[C@H](NC(CCCS(=O)(=O)C)=O)B(O)O AIQWWVDEOPVPNJ-AWEZNQCLSA-N 0.000 claims 1
- OHELUJZPYHXZDO-ZDUSSCGKSA-N C(C)C=1C=C(C=CC=1)C[C@H](NC(CCS(=O)(=O)C)=O)B(O)O Chemical compound C(C)C=1C=C(C=CC=1)C[C@H](NC(CCS(=O)(=O)C)=O)B(O)O OHELUJZPYHXZDO-ZDUSSCGKSA-N 0.000 claims 1
- SJHCWXHQYVNCFJ-FQEVSTJZSA-N C(C)N(CC(=O)N[C@@H](CC1=COC2=C1C=CC=C2C)B(O)O)S(=O)(=O)C1=CC=C(C=C1)C Chemical compound C(C)N(CC(=O)N[C@@H](CC1=COC2=C1C=CC=C2C)B(O)O)S(=O)(=O)C1=CC=C(C=C1)C SJHCWXHQYVNCFJ-FQEVSTJZSA-N 0.000 claims 1
- QIUQOQZMAOTAQU-HNNXBMFYSA-N C(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)S(=O)(=O)CC Chemical compound C(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)S(=O)(=O)CC QIUQOQZMAOTAQU-HNNXBMFYSA-N 0.000 claims 1
- UGFBYUBXVXRSAT-SFHVURJKSA-N C(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)F)B(O)O)C(C1=CC=C(C=C1)C(F)(F)F)=O Chemical compound C(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)F)B(O)O)C(C1=CC=C(C=C1)C(F)(F)F)=O UGFBYUBXVXRSAT-SFHVURJKSA-N 0.000 claims 1
- ZVFCJCYQSJZLEO-IBGZPJMESA-N C(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)F)B(O)O)C(C1=CC=C(C=C1)OC)=O Chemical compound C(C)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)F)B(O)O)C(C1=CC=C(C=C1)OC)=O ZVFCJCYQSJZLEO-IBGZPJMESA-N 0.000 claims 1
- FSMRRXIKVFGHIA-IBGZPJMESA-N C(C)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C1=C(C=CC=C1)C)=O Chemical compound C(C)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C1=C(C=CC=C1)C)=O FSMRRXIKVFGHIA-IBGZPJMESA-N 0.000 claims 1
- LHCLHTILEMMJHP-IBGZPJMESA-N C(C)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C1=CC(=CC=C1)C)=O Chemical compound C(C)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C1=CC(=CC=C1)C)=O LHCLHTILEMMJHP-IBGZPJMESA-N 0.000 claims 1
- GCYLMJAZCGNILM-IBGZPJMESA-N C(C)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C1=CC=C(C=C1)C)=O Chemical compound C(C)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C1=CC=C(C=C1)C)=O GCYLMJAZCGNILM-IBGZPJMESA-N 0.000 claims 1
- YXQGTLHNAJJLOT-IBGZPJMESA-N C(C)S(=O)(=O)N(C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O Chemical compound C(C)S(=O)(=O)N(C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O YXQGTLHNAJJLOT-IBGZPJMESA-N 0.000 claims 1
- RCYSXWCTPAJGOG-KRWDZBQOSA-N C(C1=CC=CC=C1)(=O)N(CC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)CC Chemical compound C(C1=CC=CC=C1)(=O)N(CC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)CC RCYSXWCTPAJGOG-KRWDZBQOSA-N 0.000 claims 1
- RBVSSNLLASZAHI-KRWDZBQOSA-N C(C1=CC=CC=C1)(=O)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C Chemical compound C(C1=CC=CC=C1)(=O)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C RBVSSNLLASZAHI-KRWDZBQOSA-N 0.000 claims 1
- HNVWZEPQCBHXHX-IBGZPJMESA-N C(C1=CC=CC=C1)(=O)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C)C Chemical compound C(C1=CC=CC=C1)(=O)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)C(C)C HNVWZEPQCBHXHX-IBGZPJMESA-N 0.000 claims 1
- HCDHJVORFMVUQH-SFHVURJKSA-N C(C1=CC=CC=C1)(=O)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)CC Chemical compound C(C1=CC=CC=C1)(=O)N(CCC(=O)N[C@@H](CC1=CC=CC=C1)B(O)O)CC HCDHJVORFMVUQH-SFHVURJKSA-N 0.000 claims 1
- HOLVETWWICWDGF-SFHVURJKSA-N C1(=CC=CC=C1)S(=O)(=O)CCC(=O)N[C@@H](CC1=COC2=C1C=CC=C2)B(O)O Chemical compound C1(=CC=CC=C1)S(=O)(=O)CCC(=O)N[C@@H](CC1=COC2=C1C=CC=C2)B(O)O HOLVETWWICWDGF-SFHVURJKSA-N 0.000 claims 1
- TZLRQKUTFVWMJA-QHCPKHFHSA-N C1(=CC=CC=C1)S(=O)(=O)N(C1=CC=CC=C1)CC(=O)N[C@@H](CC1=C(C=C(C=C1)C)C)B(O)O Chemical compound C1(=CC=CC=C1)S(=O)(=O)N(C1=CC=CC=C1)CC(=O)N[C@@H](CC1=C(C=C(C=C1)C)C)B(O)O TZLRQKUTFVWMJA-QHCPKHFHSA-N 0.000 claims 1
- XPJCXKKOWHLCSO-SFHVURJKSA-N C1(=CC=CC=C1)S(=O)(=O)N(CC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)CC Chemical compound C1(=CC=CC=C1)S(=O)(=O)N(CC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)CC XPJCXKKOWHLCSO-SFHVURJKSA-N 0.000 claims 1
- LWAOBMSRYCCZMO-SFHVURJKSA-N C1(=CC=CC=C1)S(=O)(=O)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)C Chemical compound C1(=CC=CC=C1)S(=O)(=O)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)C LWAOBMSRYCCZMO-SFHVURJKSA-N 0.000 claims 1
- SRPKIKNGVKQFJK-FQEVSTJZSA-N C1(=CC=CC=C1)S(=O)(=O)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)C(C)C Chemical compound C1(=CC=CC=C1)S(=O)(=O)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)C(C)C SRPKIKNGVKQFJK-FQEVSTJZSA-N 0.000 claims 1
- VCVRMNGFZNFNOS-IBGZPJMESA-N C1(=CC=CC=C1)S(=O)(=O)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)CC Chemical compound C1(=CC=CC=C1)S(=O)(=O)N(CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O)CC VCVRMNGFZNFNOS-IBGZPJMESA-N 0.000 claims 1
- AEHOJOJHAJPVDM-NRFANRHFSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CCN(C(C1=CC=C(C=C1)C)=O)CC)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CCN(C(C1=CC=C(C=C1)C)=O)CC)=O)B(O)O AEHOJOJHAJPVDM-NRFANRHFSA-N 0.000 claims 1
- GVJFAUOIGORIIP-HNNXBMFYSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(C(CC)=O)CC)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(C(CC)=O)CC)=O)B(O)O GVJFAUOIGORIIP-HNNXBMFYSA-N 0.000 claims 1
- COQPTYNKIZSGGO-HNNXBMFYSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(C(CSC)=O)CC)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(C(CSC)=O)CC)=O)B(O)O COQPTYNKIZSGGO-HNNXBMFYSA-N 0.000 claims 1
- OGMRIPIUIOSRHL-IBGZPJMESA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(C1=CC=CC=C1)C(CC)=O)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(C1=CC=CC=C1)C(CC)=O)=O)B(O)O OGMRIPIUIOSRHL-IBGZPJMESA-N 0.000 claims 1
- CXFGOGSYWFKMJT-FQEVSTJZSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=C(C=CC=C1)C)CC)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=C(C=CC=C1)C)CC)=O)B(O)O CXFGOGSYWFKMJT-FQEVSTJZSA-N 0.000 claims 1
- HPPQAGJUZCZPQV-NRFANRHFSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)C(C)C)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)C(C)C)=O)B(O)O HPPQAGJUZCZPQV-NRFANRHFSA-N 0.000 claims 1
- KHUUMNZXGCOPFW-IBGZPJMESA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)C)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)C)=O)B(O)O KHUUMNZXGCOPFW-IBGZPJMESA-N 0.000 claims 1
- ORXZZQLTYXOLKA-FQEVSTJZSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)CC)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)CC)=O)B(O)O ORXZZQLTYXOLKA-FQEVSTJZSA-N 0.000 claims 1
- PYKFJTXFNSEJKN-FQEVSTJZSA-N CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C=1C=C(C=CC=1)C)CC)=O)B(O)O Chemical compound CC1=C(C=CC(=C1)C)C[C@H](NC(CN(S(=O)(=O)C=1C=C(C=CC=1)C)CC)=O)B(O)O PYKFJTXFNSEJKN-FQEVSTJZSA-N 0.000 claims 1
- DYRXZHVPQBFXLL-HNNXBMFYSA-N CN(C(CCCC(=O)N[C@@H](CC1=CC(=CC=C1)CC)B(O)O)=O)C Chemical compound CN(C(CCCC(=O)N[C@@H](CC1=CC(=CC=C1)CC)B(O)O)=O)C DYRXZHVPQBFXLL-HNNXBMFYSA-N 0.000 claims 1
- GWLWBYOONUMANQ-AWEZNQCLSA-N CN(CC(=O)N[C@@H](CC1=CSC=C1)B(O)O)C(C1=C(C=CC=C1)C(F)(F)F)=O Chemical compound CN(CC(=O)N[C@@H](CC1=CSC=C1)B(O)O)C(C1=C(C=CC=C1)C(F)(F)F)=O GWLWBYOONUMANQ-AWEZNQCLSA-N 0.000 claims 1
- HHEFGYFURUBSPT-SFHVURJKSA-N CS(=O)(=O)N(C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O Chemical compound CS(=O)(=O)N(C1=CC=CC=C1)CCC(=O)N[C@@H](CC1=CC=C(C=C1)C)B(O)O HHEFGYFURUBSPT-SFHVURJKSA-N 0.000 claims 1
- IXFSPHUUMLLFLC-HNNXBMFYSA-N FC1=C(N(C(CC)=O)CC(=O)N[C@@H](CC2=CSC=C2)B(O)O)C=CC=C1 Chemical compound FC1=C(N(C(CC)=O)CC(=O)N[C@@H](CC2=CSC=C2)B(O)O)C=CC=C1 IXFSPHUUMLLFLC-HNNXBMFYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- FOAXYYHZDXCCIL-OYKVQYDMSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(C(C(=O)N(C)C)C1=CC=CC=C1)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(C(C(=O)N(C)C)C1=CC=CC=C1)=O)B(O)O FOAXYYHZDXCCIL-OYKVQYDMSA-N 0.000 claims 1
- CFLYLPIGJQCYKH-ZDUSSCGKSA-N O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCS(=O)(=O)C)=O)B(O)O Chemical compound O1C=C(C2=C1C=CC=C2)C[C@H](NC(CCS(=O)(=O)C)=O)B(O)O CFLYLPIGJQCYKH-ZDUSSCGKSA-N 0.000 claims 1
- XJEASXKZHYJEND-UTKZUKDTSA-N O1C[C@H](C2=C1C=CC=C2)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)C(C)C)=O)B(O)O Chemical compound O1C[C@H](C2=C1C=CC=C2)C[C@H](NC(CN(S(=O)(=O)C1=CC=C(C=C1)C)C(C)C)=O)B(O)O XJEASXKZHYJEND-UTKZUKDTSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000006303 iodophenyl group Chemical group 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14003391 | 2014-10-01 | ||
| EP14003391.1 | 2014-10-01 | ||
| PCT/EP2015/001931 WO2016050356A1 (en) | 2014-10-01 | 2015-10-01 | Boronic acid derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017115191A true RU2017115191A (ru) | 2018-11-06 |
| RU2017115191A3 RU2017115191A3 (OSRAM) | 2019-02-12 |
Family
ID=51690788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017115191A RU2017115191A (ru) | 2014-10-01 | 2015-10-01 | Производные бороновой кислоты |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10253049B2 (OSRAM) |
| EP (1) | EP3201208B1 (OSRAM) |
| JP (1) | JP6896618B2 (OSRAM) |
| KR (1) | KR20170062518A (OSRAM) |
| CN (1) | CN107074885B (OSRAM) |
| AU (1) | AU2015327412B2 (OSRAM) |
| BR (1) | BR112017006349A2 (OSRAM) |
| CA (1) | CA2963198A1 (OSRAM) |
| ES (1) | ES2876287T3 (OSRAM) |
| IL (1) | IL251299A0 (OSRAM) |
| MX (1) | MX2017004043A (OSRAM) |
| RU (1) | RU2017115191A (OSRAM) |
| SG (1) | SG11201702620SA (OSRAM) |
| WO (1) | WO2016050356A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016050359A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| BR112017006368A2 (pt) | 2014-10-01 | 2017-12-19 | Merck Patent Gmbh | derivados de ácido borônico |
| SG11201702628XA (en) | 2014-10-01 | 2017-04-27 | Merck Patent Gmbh | Boronic acid derivatives |
| WO2018136401A1 (en) * | 2017-01-18 | 2018-07-26 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| JP7189203B2 (ja) | 2017-08-24 | 2022-12-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ボロン酸誘導体 |
| US20200276204A1 (en) | 2017-09-21 | 2020-09-03 | Kezar Life Sciences | Combination therapy for immunological diseases |
| KR20210038590A (ko) * | 2018-07-26 | 2021-04-07 | 메르크 파텐트 게엠베하 | 보론산 유도체 |
| CN113135943A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CA3227452A1 (en) | 2021-07-29 | 2023-02-02 | Merck Patent Gmbh | Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain |
| WO2023061445A1 (zh) * | 2021-10-14 | 2023-04-20 | 首药控股(北京)股份有限公司 | 硼酸衍生物 |
| CN117003776A (zh) * | 2022-04-29 | 2023-11-07 | 科辉智药生物科技(深圳)有限公司 | 一种硼酸类蛋白酶体抑制剂及其用途 |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| AU5788800A (en) * | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| WO2006099261A2 (en) * | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
| BRPI0820531A2 (pt) * | 2007-11-13 | 2012-07-10 | Protez Pharmaceuticals Inc | inibidores de beta-lactamase |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| MA34133B1 (fr) * | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
| EA201400735A1 (ru) * | 2011-12-22 | 2015-04-30 | Арес Трейдинг С.А. | Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы |
| CN104822689B (zh) * | 2012-12-03 | 2016-11-02 | 弗·哈夫曼-拉罗切有限公司 | 取代的三唑硼酸化合物 |
| BR112017006368A2 (pt) | 2014-10-01 | 2017-12-19 | Merck Patent Gmbh | derivados de ácido borônico |
| WO2016050359A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| SG11201702628XA (en) | 2014-10-01 | 2017-04-27 | Merck Patent Gmbh | Boronic acid derivatives |
-
2015
- 2015-10-01 BR BR112017006349A patent/BR112017006349A2/pt not_active IP Right Cessation
- 2015-10-01 CN CN201580053454.8A patent/CN107074885B/zh not_active Expired - Fee Related
- 2015-10-01 ES ES15800714T patent/ES2876287T3/es active Active
- 2015-10-01 CA CA2963198A patent/CA2963198A1/en active Pending
- 2015-10-01 RU RU2017115191A patent/RU2017115191A/ru not_active Application Discontinuation
- 2015-10-01 MX MX2017004043A patent/MX2017004043A/es unknown
- 2015-10-01 AU AU2015327412A patent/AU2015327412B2/en not_active Ceased
- 2015-10-01 WO PCT/EP2015/001931 patent/WO2016050356A1/en not_active Ceased
- 2015-10-01 US US15/516,422 patent/US10253049B2/en active Active
- 2015-10-01 EP EP15800714.6A patent/EP3201208B1/en active Active
- 2015-10-01 JP JP2017518064A patent/JP6896618B2/ja not_active Expired - Fee Related
- 2015-10-01 SG SG11201702620SA patent/SG11201702620SA/en unknown
- 2015-10-01 KR KR1020177011646A patent/KR20170062518A/ko not_active Withdrawn
-
2017
- 2017-03-21 IL IL251299A patent/IL251299A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018502048A (ja) | 2018-01-25 |
| AU2015327412A1 (en) | 2017-05-18 |
| RU2017115191A3 (OSRAM) | 2019-02-12 |
| ES2876287T3 (es) | 2021-11-12 |
| JP6896618B2 (ja) | 2021-06-30 |
| CN107074885A (zh) | 2017-08-18 |
| EP3201208A1 (en) | 2017-08-09 |
| US10253049B2 (en) | 2019-04-09 |
| IL251299A0 (en) | 2017-05-29 |
| CN107074885B (zh) | 2020-11-27 |
| MX2017004043A (es) | 2017-07-04 |
| AU2015327412B2 (en) | 2020-01-16 |
| KR20170062518A (ko) | 2017-06-07 |
| SG11201702620SA (en) | 2017-04-27 |
| EP3201208B1 (en) | 2021-03-24 |
| US20180105538A1 (en) | 2018-04-19 |
| WO2016050356A1 (en) | 2016-04-07 |
| CA2963198A1 (en) | 2016-04-07 |
| BR112017006349A2 (pt) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017115191A (ru) | Производные бороновой кислоты | |
| RU2017115193A (ru) | Производные бороновой кислоты | |
| RU2017115188A (ru) | Производные бороновой кислоты | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| ES2699267T3 (es) | Derivados alfa-amino del ácido borónico, inhibidores selectivos del inmunoproteosoma | |
| EP3419974B1 (en) | Process for the separation of enantiomers of piperazine derivatives | |
| RU2017115192A (ru) | Производные бороновой кислоты | |
| CA2687162C (en) | Heterocyclic indazole derivatives | |
| RU2015102052A (ru) | 5, 5-гетероароматические противоинфекционные соединения | |
| RU2003122190A (ru) | Производные тетрагидропиридина, их получение и применение в качестве ингибиторов клеточной пролиферации | |
| RU2004122414A (ru) | Цис-2,4,5-трифенилимидазолины и их применение для лечения опухолевых заболеваний | |
| RU2010154172A (ru) | Соединения для лечения рака | |
| BRPI0714218A2 (pt) | derivados de aminoindazolilurÉia | |
| CA2675735A1 (en) | 5-(1,3,4-oxadiazol-2-yl)-1h-indazole and 5-(1,3,4-thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes | |
| RU2013158996A (ru) | Замещенные пиридопиразины как новые ингибиторы syk | |
| CA2642232A1 (en) | Mandelic hydrazides | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| RU2005133990A (ru) | 1, 3, 4-замещенные пиразолы в качкстве антагонистов 5-ht рецепторов для психозов и неврологических нарушений | |
| RU2008119994A (ru) | Ингибиторы калиевых каналов | |
| RU2015117578A (ru) | Кетоамидные ингибиторы иммунопротеасом | |
| RU2007140578A (ru) | Ацилгидразиды в качестве ингибиторов киназ, в особенности для sgk | |
| MX2021007815A (es) | Derivados de n-(4-(oxazol-5-il)fenil)cromano-3-carboxamida y compuestos relacionados a manera de estimuladores de la producción de células precursoras de la retina para el tratamiento contra enfermedades neurorretinianas. | |
| JP2021500350A5 (OSRAM) | ||
| RU2008129625A (ru) | Замещенные производные оксазола с аналгетическим действием | |
| RU2006125509A (ru) | Полиниларилацетамиды |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20191010 |